FDA And EMA Revising GMP Rules To Address Supply Chain Deficiencies
Executive Summary
FDA and the European Medicines Agency are establishing new GMP requirements for manufacturers to identify and control the supply chains for their drug products
You may also be interested in...
Drug Shortage Rules Surface In Latest FDA Regulatory Agenda
FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.
Drug Shipments Into U.S. Could Depend On Facility Inspection; FDA Mulls Import Alerts
Foreign drug manufacturers may face refusal of their products at the U.S. border if they do not submit to an FDA inspection, another part of the agency’s growing effort to increase oversight of the global marketplace.
Drug Shipments Into U.S. Could Depend On Facility Inspection; FDA Mulls Import Alerts
Foreign drug manufacturers may face refusal of their products at the U.S. border if they do not submit to an FDA inspection, another part of the agency’s growing effort to increase oversight of the global marketplace.